1. A Review of the Clinical Effectiveness and Safety of Hybrid Cooperative Complexes in Intra-articular Viscosupplementation

   • Marcin Domżalski
   • Alberto Migliore

   Review Open access 03 May 2022 Pages: 957 - 974

2. Real-World Effectiveness of Belimumab in Systemic Lupus Erythematosus: A Systematic Literature Review

   • Shirley P. Huang
   • Sonya J. Snedecor
   • Christopher F. Bell

   Review Open access 21 May 2022 Pages: 975 - 991

   

3. COVID-19 Outcomes and Vaccination in Patients with Spondyloarthritis

   • Atul Deodhar
   • Suleman Bhana
   • Lianne S. Gensler

   Review Open access 22 May 2022 Pages: 993 - 1016

4. Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2)

   • Georg Schett
   • Matthew J. Loza
   • Kristen Sweet

   Original Research Open access 30 March 2022 Pages: 1017 - 1030

   

5. Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry

   • Manuel José Moreno-Ramos
   • Carlos Sanchez-Piedra
   • Isabel Castrejón

   Original Research Open access 25 April 2022 Pages: 1031 - 1047

   

6. Abnormalities of Peripheral Lymphocyte Subsets in Rheumatoid Arthritis Patients Complicated with Osteoporosis

   • Ting Cheng
   • Sheng-Xiao Zhang
   • Xiao-Feng Li

   Original Research Open access 02 May 2022 Pages: 1049 - 1059

   

7. Associations of Healthcare Utilization and Costs with Increasing Pain and Treatment Intensity Levels in Osteoarthritis Patients: An 18-Year Retrospective Study

   • Jove Graham
   • Tonia Novosat
   • Patricia Dorling

   Original Research Open access 10 May 2022 Pages: 1061 - 1078

   

8. Exploring the Association Between History of Psoriasis (PSO) and Disease Activity in Patients with Psoriatic Arthritis (PsA)

   • Shan-Shan Li
   • Na Du
   • Tian-Fang Li

   Original Research Open access 17 May 2022 Pages: 1079 - 1090

   

9. Diabetes-Related Complications and Costs in Medicare Beneficiaries with Comorbid Rheumatoid Arthritis and Diabetes Treated with Abatacept Versus Other Targeted DMARDs

   • Vardhaman Patel
   • Zulkarnain Pulungan
   • Kaleb Michaud

   Original Research Open access 23 May 2022 Pages: 1091 - 1107

10. The Non-medical Switch from Reference Adalimumab to Biosimilar Adalimumab is Highly Successful in a Large Cohort of Patients with Stable Inflammatory Rheumatic Joint Diseases: A Real-Life Observational Study

    • Roxanne C. S. van Adrichem
    • Hanneke J. E. Voorneveld
    • Radjesh J. Bisoendial

    Original Research Open access 03 June 2022 Pages: 1109 - 1118

    

11. Health Economic Evaluation of a High and Low Molecular Weight Hyaluronic Acid Formulation for the Treatment of Knee Osteoarthritis. Post Hoc Analyses from a Randomized Clinical Trial

    • Olivier Bruyère
    • Jean-Yves Reginster
    • Germain Honvo

    Original Research Open access 03 June 2022 Pages: 1119 - 1128

    

12. Interim 2-Year Analysis from SERENA: A Real-World Study in Patients with Psoriatic Arthritis or Ankylosing Spondylitis Treated with Secukinumab

    • Uta Kiltz
    • Petros P. Sfikakis
    • Piotr Jagiello

    Original Research Open access 08 June 2022 Pages: 1129 - 1142

    

13. Efficacy of Abatacept Versus Tumor Necrosis Factor Inhibitors in Anti-citrullinated Protein Antibody-Positive Patients with Rheumatoid Arthritis: Results from a Korean Nationwide Biologics Registry

    • Min Jung Kim
    • Sun-Kyung Lee
    • Kichul Shin

    Original Research Open access 18 June 2022 Pages: 1143 - 1155

    

14. A Randomized Pharmacokinetic Study in Healthy Male Subjects Comparing a High-concentration, Citrate-free SB5 Formulation (40 mg/0.4 ml) and Prior SB5 (Adalimumab Biosimilar)

    • So-shin Ahn
    • Minkyung Lee
    • Sukho Lee

    Original Research Open access 01 July 2022 Pages: 1157 - 1169

    

15. Association between TNFi anti-drug antibodies, smoking, and disease activity in patients with inflammatory arthritis: Results from a Norwegian cross-sectional observational study

    • Brigitte Michelsen
    • Kristine Thomassen Berget
    • Glenn Haugeberg

    Brief Report Open access 20 May 2022 Pages: 1171 - 1179

16. Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials

    • Philip Mease
    • Arthur Kavanaugh
    • Laure Gossec

    Brief Report Open access 23 May 2022 Pages: 1181 - 1191

    

17. Clinical Characteristics of Potential “Difficult-to-treat” Patients with Psoriatic Arthritis: A Retrospective Analysis of a Longitudinal Cohort

    • Fabio Massimo Perrotta
    • Silvia Scriffignano
    • Ennio Lubrano

    Brief Report Open access 25 May 2022 Pages: 1193 - 1201

18. Dactylitis and Early Onset Psoriasis in Psoriatic Arthritis: Are they Markers of Disease Severity? A Clinical Study

    • Silvia Scriffignano
    • Fabio Massimo Perrotta
    • Ennio Lubrano

    Brief Report Open access 17 June 2022 Pages: 1203 - 1211

19. Plasma Exchange in a Patient with Immune Thrombocytopenia Associated with Antiphospholipid Syndrome Hospitalized for COVID-19

    • Federico Boggio
    • Alessandro Ciavarella
    • Flora Peyvandi

    Case Report Open access 15 June 2022 Pages: 1213 - 1219

    

20. Letter to the Editor Regarding “Ultrasound Features of Adhesive Capsulitis”

    • Mathieu Boudier-Revéret
    • Ming-Yen Hsiao
    • Min Cheol Chang

    Letter to the Editor Open access 05 May 2022 Pages: 1221 - 1223

21. A Response to: Letter to the Editor Regarding Ultrasound Features of Adhesive Capsulitis

    • Salvatore Massimo Stella
    • Roberta Gualtierotti
    • Stefano Galletti

    Letter to the Editor Open access 14 May 2022 Pages: 1225 - 1228

    

22. Letter to the Editor Regarding “Colchicine Against SARS-CoV-2 Infection: What is the Evidence?”

    • Josef Finsterer

    Letter Open access 13 June 2022 Pages: 1229 - 1231

23. A Response to: Letter to the Editor Regarding the Article: “Colchicine Against SARS-CoV-2 Infection: What is the Evidence?”

    • Alexandros A. Drosos
    • Eleftherios Pelechas
    • Paraskevi V. Voulgari

    Letter Open access 27 May 2022 Pages: 1233 - 1235

24. Letter to the Editor Regarding Esophageal Dysfunction and Systemic Sclerosis: Drugs Should be Kept in Mind

    • David Bernal-Bello
    • David Serantes-Gómez
    • Begoña Frutos-Pérez

    Letter Open access 18 June 2022 Pages: 1237 - 1240

25. A Response to: Letter to the Editor Regarding [Esophageal Dysfunction and Systemic Sclerosis: Drugs Should be Kept in Mind]

    • Bo Li
    • Junqing Yan
    • Xuan Wang

    Letter Open access 18 June 2022 Pages: 1241 - 1243

26. Correction to: Real-world Treatment Patterns and Clinical Outcomes of Baricitinib in Rheumatoid Arthritis patients in Spain: Results of a multicenter, observational study in routine clinical practice (The ORBIT-RA Study)

    • Blanca Hernández-Cruz
    • José Rosas
    • Mercedes Núñez

    Correction Open access 02 June 2022 Pages: 1245 - 1246

27. Publisher Correction to: Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2)

    • Georg Schett
    • Matthew J. Loza
    • Kristen Sweet

    Publisher Correction Open access 02 July 2022 Pages: 1247 - 1248